NLRP3 and COVID-19: The effects of probiotics on gut microbiota composition may also have therapeutic actions in COVID-19 by regulating different mechanisms involved in its pathogenesis, including SARS-CoV-2 entry through ACE2 receptors, immune response activation and immunomodulation mediated by NLR family pyrin domain-containing 3 (NLRP3), immune cell recruitment responsible for associated pulmonary and cardiovascular damage, and impairment of metabolic pathways related to COVID-19 prognosis [108].